Clinical Trial Update: An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase 1 open-label study evaluating safety and tolerability of subcutaneous elamipretide in intermediate age-related macular degeneration has completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Elamipretide (elamipretide)

Snippet

Sponsor: Stealth BioTherapeutics Inc. | Conditions: Age-Related Macular Degeneration | Phase 1 | Status: COMPLETED | Results posted: 2020-09-21